Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.

Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.

A higher proportion of intermittent viremia (to have a HIV-1 RNA viral load>50 copies/mL not confirmed) was reported in the boosted protease inhibitor monotherapy arm in some studies including MONOI trial, and that could have an impact on the replenishment of the HIV-1 DNA reservoirs. The HIV-1 D...

Full description

Bibliographic Details
Main Authors: Sidonie Lambert-Niclot, Philippe Flandre, Marc-Antoine Valantin, Cathia Soulie, Slim Fourati, Marc Wirden, Sophie Sayon, Sophie Pakianather, Laurence Bocket, Bernard Masquelier, Georges Dos Santos, Christine Katlama, Vincent Calvez, Anne-Genevieve Marcelin
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3405120?pdf=render

Internet

http://europepmc.org/articles/PMC3405120?pdf=render

Similar Items